Connection
Bradley Corr to Antibodies, Bispecific
This is a "connection" page, showing publications Bradley Corr has written about Antibodies, Bispecific.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.045 |
|
|
|
-
Fu S, Corr BR, Culm-Merdek K, Mockbee C, Youssoufian H, Stagg R, Naumann RW, Wenham RM, Rosengarten RD, Benjamin L, Hamilton EP, Moore KN. Phase Ib Study of Navicixizumab Plus Paclitaxel in Patients With Platinum-Resistant Ovarian, Primary Peritoneal, or Fallopian Tube Cancer. J Clin Oncol. 2022 08 10; 40(23):2568-2577.
Score: 0.045